Latest Bioheart Inc. (BHRT) Headlines
Bioheart Boosts Team With Regulatory, Finance and Administrative Expertise
Marketwire - Fri Sep 20, 12:10PM CDT
Bioheart (OTCQB: BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, has expanded its team by adding three key strategic positions with regulatory, finance and administrative expertise.
Bioheart Inc adds Sheldon T Anderson to board
M2 - Thu Aug 29, 6:05AM CDT
Biotech company Bioheart Inc (OTCQB:BHRT) stated on Wednesday that Sheldon T Anderson has been named to its board of directors.
Sheldon T. Anderson Elected to the Board of Directors of Bioheart, Inc.
Marketwire - Wed Aug 28, 7:02AM CDT
Sheldon T. Anderson has been elected to the Board of Directors of Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease. Mr. Anderson is Chairman of the Advisory Board of Northern Trust. He retired last year as Chairman and CEO of the Southeast Region of Northern Trust, where he was responsible for managing the company's investment management, trust and estate planning, private and business banking and financial consulting business in Florida and Georgia.
Bioheart's President / CEO Mike Tomas Appointed to Workforce Florida Board of Directors by Governor Rick Scott
Marketwire - Wed Aug 14, 7:21AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors. Workforce Florida is charged with overseeing the state's workforce system and developing strategies that will improve the state's business environment while supporting its economy (www.EmployFlorida.com).
OTC Daily Alert Stock Watch - Bioheart (OTCBB:BHRT)
WorldStockWire - Tue Aug 13, 12:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Bioheart Inc wins validated FDA registration for stem tissue bank establishment
M2 - Mon Aug 12, 5:56AM CDT
Cardiovascular cell technology company Bioheart Inc (OTCQB:BHRT) said on Friday that it has been awarded a validated registration from the FDA for the initial tissue bank listing.
Bioheart Receives Validated FDA Registration for Tissue Bank Establishment
Marketwire - Fri Aug 09, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. This new business unit will create an additional revenue stream for Bioheart. Patients can store stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart Announces Phase III MIRROR Trial for MyoCell Initiated
Marketwire - Tue Jul 02, 2:38PM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell(R) or muscle derived stem cells.
Bioheart Inc concludes Phase I ANGEL trial in congestive heart failure patients
M2 - Thu Jun 13, 4:14AM CDT
Cell therapies company Bioheart Inc (OTCQB:BHRT) said on Wednesday that it has treated all patients in the phase I ANGEL Trial following a brief enrolment.
Bioheart Announces Phase I ANGEL Trial Completed
Marketwire - Wed Jun 12, 6:09AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated all patients in the phase I ANGEL Trial. The trial, which is fully funded by Bioheart, is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of adipose-derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.
Bioheart Announces First Patients Successfully Enrolled and Treated in ANGEL Trial
Marketwire - Fri May 31, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated the first patients in the ANGEL Trial. The trial which is fully funded by Bioheart is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I ANGEL study will provide necessary safety and preliminary efficacy of adipose derived stem cells in patients with congestive heart failure.
Bioheart Announces Addition of New Corporate Controller
Marketwire - Wed May 15, 6:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Ms. Evelyn Flores will join Bioheart as Corporate Controller. A tenured finance and accounting executive, Ms. Flores has over 15 years of public and private company experience in tax and audit preparation, SOX narratives, matrix preparation and SEC filings. Ms. Flores earned a BS in Accounting and Finance from the University of Illinois and an MBA in Accounting and Finance from Nova Southeastern University.
Bioheart Discusses Current Clinical Program on Live Public Webinar
Marketwire - Tue Apr 23, 6:24AM CDT
Bioheart, Inc. (OTCQB: BHRT) a leader within the cardiovascular sector delivering cell therapies and biologics that help address congestive heart failure announced today that it will host a live webinar open to the public after market close on April 30th 2013. Chief Science Officer, Kristin Comella, will present a summary of Bioheart's clinical program results to date. A recording of the webinar will be provided after the event.
Bioheart Inc concludes tissue bank FDA registration process
M2 - Wed Apr 03, 6:26AM CDT
Cell technology company Bioheart Inc (OTCQB:BHRT) reported on Tuesday the completion of the FDA tissue bank registration process to conduct trials on LipiCell (adipose derived stem cells) in a variety of degenerative diseases.
Bioheart Completes FDA Registration for Tissue Bank Establishment
Marketwire - Tue Apr 02, 6:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the FDA tissue bank registration process. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. Patients can store additional stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart's Appeals to the FDA for Compassionate Use Designation to Save Lives
Marketwire - Wed Mar 27, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) today announced that the Company is preparing to request of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) permission to allow access to investigational drugs outside of a clinical trial setting. Bioheart's cell therapy products address an unmet need in the cardiac market by providing true regenerative medicine where the MyoCell(R) product line may regenerate muscle in areas of scar tissue and the LipiCell(R) product may help reduce inflammation and promote the growth of new blood vessels.
Bioheart CEO Mike Tomas Honored for Community and Business Endeavors
Marketwire - Mon Mar 25, 6:17AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the Company's President/CEO has received multiple accolades and honors from both national and international assemblages.
Bioheart Secures Investment and Announces Immediate Launching of ANGEL Trial
Marketwire - Thu Mar 21, 7:10AM CDT
Bioheart, Inc. (OTCQB: BHRT) has announced that it has secured the necessary funding for the ANGEL trial. This trial will initiate in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). The phase one trial will test the safety and efficacy of LipiCell(TM) (adipose derived stem cells) in congestive heart failure patients. The first cohort of five patients will be completed and analyzed to help establish a safety profile and preliminary efficacy.
Bioheart Expands Center of Excellence Program
Marketwire - Tue Mar 19, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has expanded its Center of Excellence program to include a clinical site in Jamaica with the American Stem Cell and Anti-Aging Center. This site is in addition to the existing centers in Turkey, the Czech Republic and Mexico. American Stem Cell and Anti-Aging Center provides therapies for a variety of degenerative diseases at a fully equipped state-of-the-art private specialties hospital.
Bioheart Inc adds Kristin Comella to board
M2 - Fri Mar 15, 7:10AM CDT
Cardiovascular company Bioheart Inc (OTCQB:BHRT) stated on Thursday the election of Kristin C Comella to the board of directors.
Bioheart Boosts Team With Regulatory, Finance and Administrative Expertise
Marketwire - Fri Sep 20, 12:10PM CDT
Bioheart (OTCQB: BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, has expanded its team by adding three key strategic positions with regulatory, finance and administrative expertise.
Bioheart Inc adds Sheldon T Anderson to board
M2 - Thu Aug 29, 6:05AM CDT
Biotech company Bioheart Inc (OTCQB:BHRT) stated on Wednesday that Sheldon T Anderson has been named to its board of directors.
Sheldon T. Anderson Elected to the Board of Directors of Bioheart, Inc.
Marketwire - Wed Aug 28, 7:02AM CDT
Sheldon T. Anderson has been elected to the Board of Directors of Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease. Mr. Anderson is Chairman of the Advisory Board of Northern Trust. He retired last year as Chairman and CEO of the Southeast Region of Northern Trust, where he was responsible for managing the company's investment management, trust and estate planning, private and business banking and financial consulting business in Florida and Georgia.
Bioheart's President / CEO Mike Tomas Appointed to Workforce Florida Board of Directors by Governor Rick Scott
Marketwire - Wed Aug 14, 7:21AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors. Workforce Florida is charged with overseeing the state's workforce system and developing strategies that will improve the state's business environment while supporting its economy (www.EmployFlorida.com).
OTC Daily Alert Stock Watch - Bioheart (OTCBB:BHRT)
WorldStockWire - Tue Aug 13, 12:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Bioheart Inc wins validated FDA registration for stem tissue bank establishment
M2 - Mon Aug 12, 5:56AM CDT
Cardiovascular cell technology company Bioheart Inc (OTCQB:BHRT) said on Friday that it has been awarded a validated registration from the FDA for the initial tissue bank listing.
Bioheart Receives Validated FDA Registration for Tissue Bank Establishment
Marketwire - Fri Aug 09, 7:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. This new business unit will create an additional revenue stream for Bioheart. Patients can store stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart Announces Phase III MIRROR Trial for MyoCell Initiated
Marketwire - Tue Jul 02, 2:38PM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today the successful enrollment and randomization of the first patient in the Phase III MIRROR Trial using MyoCell(R) or muscle derived stem cells.
Bioheart Inc concludes Phase I ANGEL trial in congestive heart failure patients
M2 - Thu Jun 13, 4:14AM CDT
Cell therapies company Bioheart Inc (OTCQB:BHRT) said on Wednesday that it has treated all patients in the phase I ANGEL Trial following a brief enrolment.
Bioheart Announces Phase I ANGEL Trial Completed
Marketwire - Wed Jun 12, 6:09AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated all patients in the phase I ANGEL Trial. The trial, which is fully funded by Bioheart, is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of adipose-derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.
Bioheart Announces First Patients Successfully Enrolled and Treated in ANGEL Trial
Marketwire - Fri May 31, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated the first patients in the ANGEL Trial. The trial which is fully funded by Bioheart is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I ANGEL study will provide necessary safety and preliminary efficacy of adipose derived stem cells in patients with congestive heart failure.
Bioheart Announces Addition of New Corporate Controller
Marketwire - Wed May 15, 6:01AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Ms. Evelyn Flores will join Bioheart as Corporate Controller. A tenured finance and accounting executive, Ms. Flores has over 15 years of public and private company experience in tax and audit preparation, SOX narratives, matrix preparation and SEC filings. Ms. Flores earned a BS in Accounting and Finance from the University of Illinois and an MBA in Accounting and Finance from Nova Southeastern University.
Bioheart Discusses Current Clinical Program on Live Public Webinar
Marketwire - Tue Apr 23, 6:24AM CDT
Bioheart, Inc. (OTCQB: BHRT) a leader within the cardiovascular sector delivering cell therapies and biologics that help address congestive heart failure announced today that it will host a live webinar open to the public after market close on April 30th 2013. Chief Science Officer, Kristin Comella, will present a summary of Bioheart's clinical program results to date. A recording of the webinar will be provided after the event.
Bioheart Inc concludes tissue bank FDA registration process
M2 - Wed Apr 03, 6:26AM CDT
Cell technology company Bioheart Inc (OTCQB:BHRT) reported on Tuesday the completion of the FDA tissue bank registration process to conduct trials on LipiCell (adipose derived stem cells) in a variety of degenerative diseases.
Bioheart Completes FDA Registration for Tissue Bank Establishment
Marketwire - Tue Apr 02, 6:23AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the FDA tissue bank registration process. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. Patients can store additional stem cell doses in liquid nitrogen for future use in approved clinical trials. These trials focus on the use of LipiCell(TM) (adipose derived stem cells) in a variety of different degenerative diseases.
Bioheart's Appeals to the FDA for Compassionate Use Designation to Save Lives
Marketwire - Wed Mar 27, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) today announced that the Company is preparing to request of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) permission to allow access to investigational drugs outside of a clinical trial setting. Bioheart's cell therapy products address an unmet need in the cardiac market by providing true regenerative medicine where the MyoCell(R) product line may regenerate muscle in areas of scar tissue and the LipiCell(R) product may help reduce inflammation and promote the growth of new blood vessels.
Bioheart CEO Mike Tomas Honored for Community and Business Endeavors
Marketwire - Mon Mar 25, 6:17AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the Company's President/CEO has received multiple accolades and honors from both national and international assemblages.
Bioheart Secures Investment and Announces Immediate Launching of ANGEL Trial
Marketwire - Thu Mar 21, 7:10AM CDT
Bioheart, Inc. (OTCQB: BHRT) has announced that it has secured the necessary funding for the ANGEL trial. This trial will initiate in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). The phase one trial will test the safety and efficacy of LipiCell(TM) (adipose derived stem cells) in congestive heart failure patients. The first cohort of five patients will be completed and analyzed to help establish a safety profile and preliminary efficacy.
Bioheart Expands Center of Excellence Program
Marketwire - Tue Mar 19, 6:00AM CDT
Bioheart, Inc. (OTCQB: BHRT) announced today that it has expanded its Center of Excellence program to include a clinical site in Jamaica with the American Stem Cell and Anti-Aging Center. This site is in addition to the existing centers in Turkey, the Czech Republic and Mexico. American Stem Cell and Anti-Aging Center provides therapies for a variety of degenerative diseases at a fully equipped state-of-the-art private specialties hospital.
Bioheart Inc adds Kristin Comella to board
M2 - Fri Mar 15, 7:10AM CDT
Cardiovascular company Bioheart Inc (OTCQB:BHRT) stated on Thursday the election of Kristin C Comella to the board of directors.
